B7-33 — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

B7-33

Also known as: B7-33 peptide, single-chain relaxin mimetic, H2 relaxin B-chain analogue, relaxin peptidomimetic, single-B-chain relaxin derivative

Synthetic single-chain peptide; functionally selective RXFP1 (Relaxin Family Peptide Receptor 1) agonist; relaxin mimetic

Research chemicalLast updated: November 4, 2026Based on 14 peer-reviewed studiesPreclinical data only — no human trials

What it is

Researchers are studying B7-33 for its potential to reduce fibrosis — the buildup of scar tissue — in the heart, lungs, and kidneys. It activates the same protective receptor as relaxin, a natural hormone the body uses during pregnancy to remodel tissue. No FDA-approved use; evidence comes from animal studies and early in vitro work.

The scientific side

B7-33 is a synthetic single-chain peptide derived from the B-chain of human relaxin-2 (H2 relaxin). It binds to and activates the G protein-coupled receptor RXFP1 (Relaxin Family Peptide Receptor 1), acting as a functionally selective agonist by preferentially activating the pERK1/2 (extracellular signal-regulated kinase 1/2) pathway over the cAMP signaling pathway in cells that endogenously express RXFP1. This functional selectivity distinguishes B7-33 from native H2 relaxin, which strongly activates both cAMP and ERK pathways; the strong cAMP activation of H2 relaxin has been associated with potential tumor-promoting actions. The anti-fibrotic actions of B7-33 involve activation of RXFP1-angiotensin II type 2 receptor heterodimers, leading to downstream signaling through pERK1/2 and the collagen-degrading enzyme matrix metalloproteinase-2 (MMP-2). In the cardiovascular context, B7-33 reduces infarct size and adverse cardiac remodeling partly by attenuating cardiomyocyte death and endoplasmic reticulum stress via an ERK1/2-dependent mechanism. B7-33 has demonstrated poor affinity and potency in HEK cells overexpressing RXFP1, but equivalent potency to H2 relaxin in fibroblasts natively expressing RXFP1, where it replicates anti-fibrotic effects of the native hormone. In an anti-fibrotic nanotechnology context, B7-33 has also been described as an inducer of fibroblast quiescence.

Class: Synthetic single-chain peptide; functionally selective RXFP1 (Relaxin Family Peptide Receptor 1) agonist; relaxin mimetic

Administration & storage

Administration
Intravenous tail vein injection (acute bolus; PMID: 28478069)Subcutaneous injection (daily; PMID: 36753958)Intracerebroventricular injection (PMID: 34159282)Oral gavage via SPION nanoparticle conjugate (PMID: 41382190)Drinking water administration via SPION nanoparticle conjugate (PMID: 41382190)Intraperitoneal injection (vobramitamab duocarmazine ADC in xenograft models — note: this is an anti-B7-H3 ADCnot the B7-33 peptide; PMID: 41941262)
Storage
No storage conditions for B7-33 are described in the reviewed abstracts. The lipidated B7-33 derivative study reported an in vitro serum half-life of ~6 min for unmodified B7-33, extended to ~60 min with fatty-acid conjugation, but did not describe storage requirements.
Cautions
All B7-33 studies in the reviewed abstracts are preclinical (animal or in vitro); no human pharmacokinetic, safety, or tolerability data are available from the reviewed literature.,B7-33 has a short in vitro serum half-life of approximately 6 minutes in its unmodified form; this may limit systemic exposure duration.,Native H2 relaxin (the parent hormone) has been associated with tumor-promoting actions attributed to strong cAMP activation; B7-33 preferentially activates pERK over cAMP, and one abstract states B7-33 did not promote prostate tumor growth in preclinical models — however, long-term oncological safety of B7-33 has not been established in humans.,Sterile technique is required for any injectable preparation; this is a universal requirement for peptide injectables and not specific to B7-33.,No clinical trials of B7-33 peptide itself are described in the reviewed literature; extrapolation of animal dosing to humans is not supported by the reviewed evidence.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification. No FDA approval or status is stated for B7-33 itself. Note: The parent hormone H2 relaxin (serelaxin) was investigated for acute heart failure and…

WADA

Not stated in reviewed literature — requires manual verification.

Health Canada

Not stated in reviewed literature — requires manual verification.